[go: up one dir, main page]

WO2013109216A3 - Preparation of dry powder formulations comprising tiotropium - Google Patents

Preparation of dry powder formulations comprising tiotropium Download PDF

Info

Publication number
WO2013109216A3
WO2013109216A3 PCT/TR2013/000028 TR2013000028W WO2013109216A3 WO 2013109216 A3 WO2013109216 A3 WO 2013109216A3 TR 2013000028 W TR2013000028 W TR 2013000028W WO 2013109216 A3 WO2013109216 A3 WO 2013109216A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
preparation
dry powder
powder formulations
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2013/000028
Other languages
French (fr)
Other versions
WO2013109216A2 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP13738848.4A priority Critical patent/EP2804591A2/en
Publication of WO2013109216A2 publication Critical patent/WO2013109216A2/en
Publication of WO2013109216A3 publication Critical patent/WO2013109216A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to the process for the preparation of pharmaceutical formulations in dry powder form comprising tiotropium or pharmaceutically acceptable derivatives thereof in order to be used in symptomatic and/or prophylactic treatment of respiratory tract diseases, particularly asthma and COPD.
PCT/TR2013/000028 2012-01-16 2013-01-16 Preparation of dry powder formulations comprising tiotropium Ceased WO2013109216A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13738848.4A EP2804591A2 (en) 2012-01-16 2013-01-16 Preparation of dry powder formulations comprising tiotropium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/00492 2012-01-16
TR201200492 2012-01-16

Publications (2)

Publication Number Publication Date
WO2013109216A2 WO2013109216A2 (en) 2013-07-25
WO2013109216A3 true WO2013109216A3 (en) 2014-04-17

Family

ID=48237229

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2013/000025 Ceased WO2013109213A2 (en) 2012-01-16 2013-01-16 Pharmaceutical formulations comprising tiotropium
PCT/TR2013/000028 Ceased WO2013109216A2 (en) 2012-01-16 2013-01-16 Preparation of dry powder formulations comprising tiotropium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000025 Ceased WO2013109213A2 (en) 2012-01-16 2013-01-16 Pharmaceutical formulations comprising tiotropium

Country Status (2)

Country Link
EP (1) EP2804591A2 (en)
WO (2) WO2013109213A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136919A1 (en) * 2002-11-28 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
WO2011093819A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic New combination comprising tiotropium
WO2011093820A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising tiotropium
WO2011152804A2 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136919A1 (en) * 2002-11-28 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
WO2011093819A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic New combination comprising tiotropium
WO2011093820A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising tiotropium
WO2011152804A2 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations

Also Published As

Publication number Publication date
WO2013109216A2 (en) 2013-07-25
WO2013109213A2 (en) 2013-07-25
WO2013109213A3 (en) 2013-09-06
EP2804591A2 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
IL223795A (en) Tetrahydro-pyrido-pyrimidine derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
IL230874A (en) Bicyclic dihydroquinolin-2-one derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
WO2014064410A3 (en) Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
IL222120A (en) (indol-1-yl)-carbonylalkyl derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer
HK1206670A1 (en) Method and apparatus
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
TR201000681A2 (en) Dry powder formulations inhaled.
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
ZA201401568B (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
WO2011152804A3 (en) Process for dry powder formulations
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
IL213983A (en) Heteroaryl substituted pyridazinone derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
TR201000623A2 (en) New tiotropium combination.
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2014167579A3 (en) Stable pharmaceutical compositions of tadalafil
WO2015049519A3 (en) Method and apparatus for making compositions for pulmonary administration
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
UA115989C2 (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
WO2013109216A3 (en) Preparation of dry powder formulations comprising tiotropium

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2013738848

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13738848

Country of ref document: EP

Kind code of ref document: A2